8-Year Survival of Patients with Breast Cancer According to Stage: I- 90% II- 70% III- 40% IV- 10%
Risk categories for women with node-negative breast cancer LOW RISK: tumor size (<=1CM) AND ER or PR (positive) AND tumor grade (grade 1) INTERMEDIATE RISK: tumor size (1-2CM) AND ER or PR (positive) AND tumor grade (grade 1-2) HIGH-RISK: tumor size (>2 CM) OR ER or PR (negative) OR tumor grade (grade 2-3) ____________________________________________________ Adjuvant systemic treatment options for women with axillary node-negative breast cancer PREMENOPAUSAL ER or PR POSITIVE LOW RIK: no treatment or tamoxifen INTERMEDIATE RISK: tamoxifen+chemotherapy or tamoxifen alone, or ovarian ablation, or GnRH analogue HIGH RISK:Chemotherapy+tamoxifen or chemotherapy + ovarian ablation or GnRH analogue or chemotherapy + tamoxifen + ablation or GnRH analoguetion or GnRH analogue PREMENOPAUSAL ER or PR NEGATIVE HIGH RISK: Chemotherapy POSTMENOPAUSAL ER or PR POSITIVE LOW RIK: no treatment or tamoxifen INTERMEDIATE RISK: tamoxifen+chemotherapy or tamoxifen alone HIGH RISK: tamoxifen+chemotherapy or tamoxifen alone POSTMENOPAUSAL ER or PR NEGATIVE HIGH RISK: Chemotherapy >70 YEARS OLD LOW RIK: no treatment or tamoxifen INTERMEDIATE RISK: tamoxifen+chemotherapy or tamoxifen alone HIGH RISK: tamoxifen; chemotherapy if ER/PR negative ____________________________________________________ Adjuvant systemic treatment options for women with axillary node-positive breast cancer PREMENOPAUSAL ER or PR POSITIVE Chemotherapy + Tamoxifen, or chemotherapy + ovarian ablation/GnRH analogue. or chemotherapy + tamoxifen +ovarian ablation/GnRH analogue PREMENOPAUSAL ER or PR NEGATIVE Chemotherapy POSTMENOPAUSAL ER or PR POSITIVE Tamoxifen plus chemotherapy, tamoxifen alone POSTMENOPAUSAL ER or PR NEGATIVE Chemotherapy >70 YEARS OLD Tamoxifen; chemotherapy if ER/PR negative |